Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
61.97
+1.79 (2.97%)
At close: Oct 28, 2025, 4:00 PM EDT
63.00
+1.03 (1.66%)
After-hours: Oct 28, 2025, 4:36 PM EDT
Cytokinetics Revenue
Cytokinetics had revenue of $66.77M in the quarter ending June 30, 2025, with 26,714.86% growth. This brings the company's revenue in the last twelve months to $85.74M, up 2,635.74% year-over-year. In the year 2024, Cytokinetics had annual revenue of $18.47M with 145.34% growth.
Revenue (ttm)
$85.74M
Revenue Growth
+2,635.74%
P/S Ratio
83.15
Revenue / Employee
$172,165
Employees
498
Market Cap
7.42B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18.47M | 10.94M | 145.34% |
| Dec 31, 2023 | 7.53M | -87.06M | -92.04% |
| Dec 31, 2022 | 94.59M | 24.16M | 34.30% |
| Dec 31, 2021 | 70.43M | 14.60M | 26.15% |
| Dec 31, 2020 | 55.83M | 28.96M | 107.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CYTK News
- 38 minutes ago - Cytokinetics has been on a tear as the biotech pioneers more drugs to fight heart ailments - CNBC
- 5 days ago - CYTK INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - PRNewsWire
- 6 days ago - Cytokinetics to Announce Third Quarter Results on November 5, 2025 - GlobeNewsWire
- 11 days ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 16 days ago - CYTK INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - GlobeNewsWire
- 21 days ago - CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm - PRNewsWire
- 4 weeks ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - GlobeNewsWire
- 4 weeks ago - Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025 - GlobeNewsWire